FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 360:2781-2783 June 25, 2009 Number 26 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear Related Article by Shah, S. P. PubMed Citation

In a remarkably short time, the use of massively parallel technologies has greatly reduced the cost of DNA sequencing.¹ Already, these technologies have permitted the whole-genome sequencing of several persons^2,3,4 and one tumor⁵ for a small fraction of the cost of the sequencing of the first human genome. However, the cost of whole-genome sequencing is still many tens of thousands of dollars — too expensive for routine application to even modest numbers of samples in either a research or a clinical setting.

In this issue of the Journal, Shah et al.⁶ describe the identification of a likely "driver" mutation of . . . [Full Text of this Article]

Source Information

From the Department of Genome Sciences, University of Washington, Seattle (J.S.); and the King Edward Memorial Hospital and Bendat Cancer Centre at St. John of God Hospital — both in Perth, Australia (C.J.S.).

This article (10.1056/NEJMe0903433) was published on June 10, 2009, at NEJM.org.

This article has been cited by other articles:

• Mardis, E. R., Wilson, R. K. (2009). Cancer genome sequencing: a review. Hum Mol Genet 18: R163-R168 [Abstract] [Full Text]  
• (2009). Pathogenesis of Granulosa-Cell Tumors of the Ovaries. JWatch Oncology and Hematology 2009: 4-4 [Full Text]